EUVIMEDEUVIMED entdecken
Open Access

COCA: a randomized Bayesian design integrating dose optimization and component contribution assessment for combination therapies

Xiaohan Chi iD, Ruitao Lin iD, Ying Yuan iD

Biometrics · 2025

DOI: 10.1093/biomtc/ujaf077 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biometrics, 2025. Verfasst von Xiaohan Chi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States. Hauptthemen laut MEDLINE: Randomized Controlled Trials as Topic. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NLM NIH HHS, NCI NIH HHS, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In cancer treatment, the development of combination therapies requires demonstrating the contribution of each individual drug and optimizing the dose during early-phase trials. This necessitates a large sample size, presenting formidable obstacles for drug developers. To address this issue, we propose a 2-stage randomized phase II design that seamlessly integrates combination dose optimization with component contribution assessment. In stage 1, the optimal combination dose is determined by maximizing the risk–benefit tradeoff across multiple candidate combination doses. In stage 2, a multi-arm randomized phase is initiated to evaluate the contribution of each component within the combination therapy. To increase trial efficiency and reduce the sample size, efficacy data from both stages are adaptively combined using a Bayesian logistic regression model with a spike-and-slab prior. The sample size and decision cutoffs of the proposed design are systematically determined based on a novel calibration procedure to achieve desired operating characteristics. Extensive simulation studies show that the proposed design achieves the dual goals of dose optimization and contribution assessment, while yielding substantial sample size savings compared to competing designs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Randomized Controlled Trials as TopicBayes TheoremHumansSample SizeComputer SimulationDrug Therapy, CombinationDose-Response Relationship, DrugNeoplasmsLogistic ModelsClinical Trials, Phase II as Topic

Stichwörter der Autor:innen

combination therapycomponent contributiondose optimizationinformation borrowingmulti-arm randomized trial

Autor:innen und Institutionen

  • Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.

ORCID-Profile: Xiaohan Chi, Ruitao Lin, Ying Yuan

Förderung

  • NLM NIH HHS
  • NCI NIH HHS
  • NIH HHS
  • National Institutes of Health
  • National Cancer Institute

Zitieren

APA

Chi, X., Lin, R., & Yuan, Y. (2025). COCA: a randomized Bayesian design integrating dose optimization and component contribution assessment for combination therapies. Biometrics. https://doi.org/10.1093/biomtc/ujaf077

Vancouver

Chi X, Lin R, Yuan Y. COCA: a randomized Bayesian design integrating dose optimization and component contribution assessment for combination therapies. Biometrics. 2025. doi:10.1093/biomtc/ujaf077

BibTeX
@article{Chi2025,
  author = {Chi, Xiaohan and Lin, Ruitao and Yuan, Ying},
  title = {COCA: a randomized Bayesian design integrating dose optimization and component contribution assessment for combination therapies},
  journal = {Biometrics},
  year = {2025},
  doi = {10.1093/biomtc/ujaf077}
}
Kostenlos starten →